Madurai
Madurai
Madurai, Tamil Nadu, India27 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency | Bone Diseases, Developmental, Bone Diseases, Endocrine, Dwarfism, bone disorder, brain disorder, central nervous system disorder, endocrine system disorder, hypopituitarism, hypothalamic disorder, musculoskeletal system disorder, nervous system disorder, pituitary dwarfism, pituitary gland disorder | Recruiting | Phase 3 | 2026-10-09 | NCT06948214 | |
| A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Active, not recruiting | Phase 3 | 2026-10-07 | NCT03811561 | |
| Parasitic Ulcer Treatment Trial | Acanthamoeba keratitis, Infections, amebiasis, corneal disorder, corneal ulcer, eye disorder, eye infectious disorder, keratitis, parasitic eye infection, parasitic infectious disease, protozoa infectious disease | Recruiting | Phase 3 | 2026-10-01 | NCT06213649 | |
| Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-10-01 | NCT02227251 | |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-09-30 | NCT05519085 | |
| Left Bundle Branch Area Pacing (LBBAP) PMCF Study | Arrhythmias, Cardiac, Bradycardia, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder, heart failure | Recruiting | Not applicable | 2026-09-25 | NCT07217392 | |
| This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis | acute pyelonephritis | Not yet recruiting | Phase 2 | 2026-09-24 | NCT07840105 | |
| A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India. | Bone Diseases, Developmental, Bone Diseases, Endocrine, Dwarfism, bone disorder, brain disorder, central nervous system disorder, endocrine system disorder, hypopituitarism, hypothalamic disorder, musculoskeletal system disorder, nervous system disorder, pituitary dwarfism, pituitary gland disorder | Recruiting | Not stated | 2026-09-24 | NCT06587035 | |
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-22 | NCT06875310 | |
| A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Active, not recruiting | Phase 2 | 2026-09-17 | NCT07052006 | |
| A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) | Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Recruiting | Phase 3 | 2026-09-14 | NCT06929273 | |
| A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2026-09-11 | NCT06646276 | |
| A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia | Warm Autoimmune Hemolytic Anemia (wAIHA) | Active, not recruiting | Phase 3 | 2026-09-11 | NCT05648968 | |
| Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Treatment-Resistant, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-10 | NCT07184619 | |
| A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT05739383 | |
| Magnetic Resonance Imaging Based Risk Stratification for Defibrillator Implantation in Heart Failure Patients Requiring Cardiac Resynchronisation Therapy | Non Ischemic Cardiomyopathy | Recruiting | Not applicable | 2026-08-27 | NCT07791407 | |
| A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | diabetic macular edema | Active, not recruiting | Phase 4 | 2026-08-25 | NCT05224102 | |
| Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-08-25 | NCT05030428 | |
| RB-PDT for Fusarium Keratitis: The LUMIERE Study | Fusarium Keratitis | Not yet recruiting | Phase 3 | 2026-08-17 | NCT07743489 | |
| Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II | Bacterial Keratitis | Active, not recruiting | Phase 3 | 2026-08-17 | NCT06271772 | |
| Conduction System Pacing Display Research System for SmartSync Pacing System Analyzer | Arrhythmias, Cardiac, Bradycardia, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, heart disorder | Recruiting | Not stated | 2026-07-29 | NCT07733960 | |
| A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | Bipolar and Related Disorders, Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, bipolar disorder, mood disorder, nervous system disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-06-23 | NCT07140913 | |
| Global Trial in APG2575 for Patients With CLL/SLL | chronic lymphocytic leukemia/small lymphocytic lymphoma | Recruiting | Phase 3 | 2026-06-18 | NCT06104566 | |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | Hemic and Lymphatic Diseases, Hypertrophy, Myeloproliferative Disorders, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Splenomegaly, anemia, blood platelet disease, bone marrow disorder, hematologic disorder, hemorrhagic disease, primary myelofibrosis | Active, not recruiting | Phase 3 | 2026-04-30 | NCT03165734 | |
| AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Not yet recruiting | Phase 3 | 2026-03-12 | NCT07400107 |